annotation_id large_string | subject large_string | rsid large_string | gene large_string | genotype large_string | evidence_level large_string | phenotype_category large_string | drugs large_string | phenotypes large_string | annotation_text large_string | url large_string |
|---|---|---|---|---|---|---|---|---|---|---|
1183491380 | rs1922242 | rs1922242 | ABCB1 | AA | 3 | Efficacy | fluvastatin | Hypercholesterolemia | Patients with the AA genotype and Hypercholesterolemia may have a better response to fluvastatin (a higher change in LDL-cholesterol levels) as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491380 |
1183491380 | rs1922242 | rs1922242 | ABCB1 | AT | 3 | Efficacy | fluvastatin | Hypercholesterolemia | Patients with the AT genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in LDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491380 |
1183491380 | rs1922242 | rs1922242 | ABCB1 | TT | 3 | Efficacy | fluvastatin | Hypercholesterolemia | Patients with the TT genotype were not studied, however patients with the AT genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in LDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to... | https://www.clinpgx.org/clinicalAnnotation/1183491380 |
1183491385 | rs5882 | rs5882 | CETP | AA | 3 | Efficacy | fluvastatin | Hypercholesterolemia | Patients with the AA genotype were not studied, however patients with the AG genotype and Hypercholesterolemia may have a better response to fluvastatin (a higher change in triglycerides) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvasta... | https://www.clinpgx.org/clinicalAnnotation/1183491385 |
1183491385 | rs5882 | rs5882 | CETP | AG | 3 | Efficacy | fluvastatin | Hypercholesterolemia | Patients with the AG genotype and Hypercholesterolemia may have a better response to fluvastatin (a higher change in triglycerides) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491385 |
1183491385 | rs5882 | rs5882 | CETP | GG | 3 | Efficacy | fluvastatin | Hypercholesterolemia | Patients with the GG genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in triglycerides) as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491385 |
1183491390 | rs5882 | rs5882 | CETP | AA | 3 | Efficacy | simvastatin | Hypercholesterolemia | Patients with the AA genotype who have Hypercholesterolemia may have a better response to simvastatin (a greater decrease in triglyceride levels and higher increase in HDL-cholesterol levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simv... | https://www.clinpgx.org/clinicalAnnotation/1183491390 |
1183491390 | rs5882 | rs5882 | CETP | AG | 3 | Efficacy | simvastatin | Hypercholesterolemia | Patients with the AG genotype who have Hypercholesterolemia may have a better response to simvastatin (a greater decrease in triglyceride levels and higher increase in HDL-cholesterol levels) as compared to patients with the GG genotype, or may have a reduced response to simvastatin (a lower decrease in triglyceride le... | https://www.clinpgx.org/clinicalAnnotation/1183491390 |
1183491390 | rs5882 | rs5882 | CETP | GG | 3 | Efficacy | simvastatin | Hypercholesterolemia | Patients with the GG genotype who have Hypercholesterolemia may have a reduced response to simvastatin (a lower decrease in triglyceride levels and lower increase in HDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvas... | https://www.clinpgx.org/clinicalAnnotation/1183491390 |
1183491403 | rs428785 | rs428785 | ADAMTS1 | CC | 3 | Efficacy | pravastatin | Coronary Disease;Myocardial Infarction | Patients with the CC genotype may benefit less from pravastatin treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491403 |
1183491403 | rs428785 | rs428785 | ADAMTS1 | CG | 3 | Efficacy | pravastatin | Coronary Disease;Myocardial Infarction | Patients with the CG genotype may benefit less from pravastatin treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491403 |
1183491403 | rs428785 | rs428785 | ADAMTS1 | GG | 3 | Efficacy | pravastatin | Coronary Disease;Myocardial Infarction | Patients with the GG genotype may benefit more from pravastatin treatment as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491403 |
1183491446 | rs20455 | rs20455 | KIF6 | AA | 3 | Efficacy | atorvastatin | Coronary Disease;Hypercholesterolemia;Myocardial Infarction | Patients with the rs20455 AA genotype may have decreased response to atorvastatin as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin. | https://www.clinpgx.org/clinicalAnnotation/1183491446 |
1183491446 | rs20455 | rs20455 | KIF6 | AG | 3 | Efficacy | atorvastatin | Coronary Disease;Hypercholesterolemia;Myocardial Infarction | Patients with the rs20455 AG genotype may have increased response to atorvastatin treatment as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin. | https://www.clinpgx.org/clinicalAnnotation/1183491446 |
1183491446 | rs20455 | rs20455 | KIF6 | GG | 3 | Efficacy | atorvastatin | Coronary Disease;Hypercholesterolemia;Myocardial Infarction | Patients with the rs20455 GG genotype may have increased response to atorvastatin as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin. | https://www.clinpgx.org/clinicalAnnotation/1183491446 |
1183491541 | rs17238540 | rs17238540 | HMGCR | GG | 3 | Efficacy | pravastatin | null | Patients with the GG genotype were not studied, however patients with the GT genotype may have a reduced response to pravastatin treatment (lower decreases in LDL-cholesterol and total cholesterol) as compared to patients with the TT genotype. Several studies show no association between this variant and pravastatin res... | https://www.clinpgx.org/clinicalAnnotation/1183491541 |
1183491541 | rs17238540 | rs17238540 | HMGCR | GT | 3 | Efficacy | pravastatin | null | Patients with the GT genotype may have a reduced response to pravastatin treatment (lower decreases in LDL-cholesterol and total cholesterol) as compared to patients with the TT genotype. Several studies show no association between this variant and pravastatin response. Other genetic and clinical factors may also influ... | https://www.clinpgx.org/clinicalAnnotation/1183491541 |
1183491541 | rs17238540 | rs17238540 | HMGCR | TT | 3 | Efficacy | pravastatin | null | Patients with the TT genotype may have a better response to pravastatin treatment (higher decreases in LDL-cholesterol and total cholesterol) as compared to patients with the GT genotype. Several studies show no association between this variant and pravastatin response. Other genetic and clinical factors may also influ... | https://www.clinpgx.org/clinicalAnnotation/1183491541 |
1183491617 | rs17238540 | rs17238540 | HMGCR | GG | 3 | Efficacy | simvastatin | null | Patients with the GG genotype may have a reduced response to simvastatin treatment (lower reductions in LDL cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491617 |
1183491617 | rs17238540 | rs17238540 | HMGCR | GT | 3 | Efficacy | simvastatin | null | Patients with the GT genotype may have a reduced response to simvastatin treatment (lower reductions in LDL cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491617 |
1183491617 | rs17238540 | rs17238540 | HMGCR | TT | 3 | Efficacy | simvastatin | null | Patients with the TT genotype may have a better response to simvastatin treatment (higher reductions in LDL cholesterol) as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491617 |
1183491741 | rs17244841 | rs17244841 | HMGCR | AA | 3 | Efficacy | simvastatin | null | Patients with the AA genotype may have a better response to simvastatin treatment (a higher reduction in LDL-cholesterol) as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491741 |
1183491741 | rs17244841 | rs17244841 | HMGCR | AT | 3 | Efficacy | simvastatin | null | Patients with the AT genotype may have a reduced response to simvastatin treatment (a lower reduction in LDL-cholesterol) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491741 |
1183491741 | rs17244841 | rs17244841 | HMGCR | TT | 3 | Efficacy | simvastatin | null | Patients with the TT genotype may have a reduced response to simvastatin treatment (a lower reduction in LDL-cholesterol) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491741 |
1183491746 | rs17244841 | rs17244841 | HMGCR | AA | 3 | Efficacy | pravastatin | null | Patients with the AA genotype may have a better response (a higher reduction in LDL and total cholesterol) to pravastatin as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491746 |
1183491746 | rs17244841 | rs17244841 | HMGCR | AT | 3 | Efficacy | pravastatin | null | Patients with the AT genotype may have a reduced response (less reduction in LDL and total cholesterol) to pravastatin as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491746 |
1183491746 | rs17244841 | rs17244841 | HMGCR | TT | 3 | Efficacy | pravastatin | null | Patients with the TT genotype were not studied. Patients with the AT genotype may have a reduced response (less reduction in LDL and total cholesterol) to pravastatin as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491746 |
1183491775 | rs1801133 | rs1801133 | MTHFR | AA | 3 | Efficacy | pravastatin | Coronary Artery Disease;Myocardial Infarction | Patients with the AA genotype and Hypertension who are treated with pravastatin may have an increased risk of nonfatal myocardial infarction and fatal coronary heart disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491775 |
1183491775 | rs1801133 | rs1801133 | MTHFR | AG | 3 | Efficacy | pravastatin | Coronary Artery Disease;Myocardial Infarction | Patients with the AG genotype and Hypertension who are treated with pravastatin may have an increased risk of nonfatal myocardial infarction and fatal coronary heart disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491775 |
1183491775 | rs1801133 | rs1801133 | MTHFR | GG | 3 | Efficacy | pravastatin | Coronary Artery Disease;Myocardial Infarction | Patients with the GG genotype and Hypertension who are treated with pravastatin may have a decreased risk of nonfatal myocardial infarction and fatal coronary heart disease as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treat... | https://www.clinpgx.org/clinicalAnnotation/1183491775 |
1183491792 | rs352046 | rs352046 | CXCL5 | CC | 3 | Efficacy | HMG-CoA reductase inhibitors | Acute coronary syndrome | Patients with the CC genotype and Acute coronary syndrome who are treated with statins may have an increased response to treatment as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491792 |
1183491792 | rs352046 | rs352046 | CXCL5 | CG | 3 | Efficacy | HMG-CoA reductase inhibitors | Acute coronary syndrome | Patients with the CG genotype and Acute coronary syndrome who are treated with statins may have a decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491792 |
1183491792 | rs352046 | rs352046 | CXCL5 | GG | 3 | Efficacy | HMG-CoA reductase inhibitors | Acute coronary syndrome | Patients with the GG genotype and Acute coronary syndrome who are treated with statins may have a deceased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491792 |
1183491809 | rs1800629 | rs1800629 | TNF | AA | 3 | Other | atorvastatin | Acute coronary syndrome | Patients with the AA genotype were not studied. Patients with the AG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to a... | https://www.clinpgx.org/clinicalAnnotation/1183491809 |
1183491809 | rs1800629 | rs1800629 | TNF | AG | 3 | Other | atorvastatin | Acute coronary syndrome | Patients with the AG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491809 |
1183491809 | rs1800629 | rs1800629 | TNF | GG | 3 | Other | atorvastatin | Acute coronary syndrome | Patients with the GG genotype and acute coronary syndrome who are treated with atorvastatin may have an increase in lumbar bone marrow density as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491809 |
1183491822 | rs3917643 | rs3917643 | F3 | CC | 3 | Efficacy | simvastatin | Myocardial Ischemia | Patients with the CC genotype were not studied. Patients with the CT genotype and stable ischemic heart disease may have an increased response to simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491822 |
1183491822 | rs3917643 | rs3917643 | F3 | CT | 3 | Efficacy | simvastatin | Myocardial Ischemia | Patients with the CT genotype and stable ischemic heart disease may have an increased response to simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491822 |
1183491822 | rs3917643 | rs3917643 | F3 | TT | 3 | Efficacy | simvastatin | Myocardial Ischemia | Patients with the TT genotype and stable ischemic heart disease may have a reduced response to simvastatin as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491822 |
1183492023 | rs61764370 | rs61764370 | KRAS | AA | 3 | Efficacy | cetuximab;panitumumab | Neoplasms | Patients with the AA genotype and cancer may have a decreased response and survival times when treated with cetuximab or panitumumab as compared to patients with the AC or CC genotype. However, conflicting and negative evidence exists for this association. Other genetic and clinical factors may also influence response ... | https://www.clinpgx.org/clinicalAnnotation/1183492023 |
1183492023 | rs61764370 | rs61764370 | KRAS | CA | 3 | Efficacy | cetuximab;panitumumab | Neoplasms | Patients with the AC genotype and cancer may have an increased response and survival times when treated with cetuximab or panitumumab as compared to patients with the AA genotype. However, conflicting and negative evidence exists for this association. Other genetic and clinical factors may also influence response and s... | https://www.clinpgx.org/clinicalAnnotation/1183492023 |
1183492023 | rs61764370 | rs61764370 | KRAS | CC | 3 | Efficacy | cetuximab;panitumumab | Neoplasms | Patients with the CC genotype and cancer may have an increased response and survival times when treated with cetuximab or panitumumab as compared to patients with the AA genotype. However, conflicting and negative evidence exists for this association. Other genetic and clinical factors may also influence response and s... | https://www.clinpgx.org/clinicalAnnotation/1183492023 |
1183492030 | rs2279020 | rs2279020 | GABRA1 | AA | 3 | Efficacy | carbamazepine;phenytoin;valproic acid | Epilepsy | Patients with the AA genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have a decreased, but not absent, risk for drug-resistance as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-resistance. | https://www.clinpgx.org/clinicalAnnotation/1183492030 |
1183492030 | rs2279020 | rs2279020 | GABRA1 | GA | 3 | Efficacy | carbamazepine;phenytoin;valproic acid | Epilepsy | Patients with the GA genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for drug-resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-resistance. | https://www.clinpgx.org/clinicalAnnotation/1183492030 |
1183492030 | rs2279020 | rs2279020 | GABRA1 | GG | 3 | Efficacy | carbamazepine;phenytoin;valproic acid | Epilepsy | Patients with the GG genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for drug-resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-resistance. | https://www.clinpgx.org/clinicalAnnotation/1183492030 |
1183492035 | rs662799 | rs662799 | APOA5 | AA | 3 | Efficacy | atorvastatin;lovastatin;simvastatin | Hyperlipidemias | Patients with the rs662799 AA genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have a higher reduction in LDL-cholesterol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to statin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183492035 |
1183492035 | rs662799 | rs662799 | APOA5 | AG | 3 | Efficacy | atorvastatin;lovastatin;simvastatin | Hyperlipidemias | Patients with the rs662799 AG genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have less reduction in LDL-cholesterol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183492035 |
1183492035 | rs662799 | rs662799 | APOA5 | GG | 3 | Efficacy | atorvastatin;lovastatin;simvastatin | Hyperlipidemias | Patients with the rs662799 GG genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have less reduction in LDL-cholesterol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183492035 |
1183492128 | rs7412 | rs7412 | APOE | CC | 3 | Efficacy | fluvastatin | null | Patients with the CC genotype who are treated with fluvastatin may have a reduced response (a smaller reduction in LDL-cholesterol or change in HDL) as compared to patients with the CT genotype (carriers of E2). Other genetic and clinical factors may also influence a patient's response to statin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183492128 |
1183492128 | rs7412 | rs7412 | APOE | CT | 3 | Efficacy | fluvastatin | null | Patients with the CT genotype (carriers of E2) who are treated with fluvastatin may have a better response (increased reduction in LDL-cholesterol or change in HDL) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183492128 |
1183492128 | rs7412 | rs7412 | APOE | TT | 3 | Efficacy | fluvastatin | null | Patients with the TT genotype (also known as E2/E2) who are treated with fluvastatin may have a better response (increased reduction in LDL-cholesterol or change in HDL) as compared to patients with the CC genotype, although the studies did not have C homozygotes and only reported the effect for the heterozygote. Other... | https://www.clinpgx.org/clinicalAnnotation/1183492128 |
1183492181 | rs7412 | rs7412 | APOE | CC | 3 | Efficacy | pravastatin | null | Patients with the CC genotype (non-carriers of APOE E2) who are treated with pravastatin may have a reduced response (a smaller reduction in LDL-cholesterol) as compared to patients with the TT genotype (also known as APOE E2/E2). Other genetic and clinical factors may also influence a patient's response to pravastatin... | https://www.clinpgx.org/clinicalAnnotation/1183492181 |
1183492181 | rs7412 | rs7412 | APOE | CT | 3 | Efficacy | pravastatin | null | Patients with the CT genotype (carriers of APOE E2) who are treated with pravastatin may have a better response (increased reduction in LDL-cholesterol) as compared to patients with the CC genotype (non-carriers of APOE E2). Other genetic and clinical factors may also influence a patient's response to pravastatin treat... | https://www.clinpgx.org/clinicalAnnotation/1183492181 |
1183492181 | rs7412 | rs7412 | APOE | TT | 3 | Efficacy | pravastatin | null | Patients with the TT genotype (also known as APOE E2/E2) who are treated with pravastatin may have a better response (increased reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183492181 |
1183492235 | rs2230806 | rs2230806 | ABCA1 | CC | 3 | Efficacy | pravastatin | Coronary Disease | Patients with the CC genotype and Coronary Disease who are treated with pravastatin may have a reduced response (lower increases in HDL-cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183492235 |
1183492235 | rs2230806 | rs2230806 | ABCA1 | CT | 3 | Efficacy | pravastatin | Coronary Disease | Patients with the CT genotype and Coronary Disease who are treated with pravastatin may have a better response (increased HDL-cholesterol) as compared to patients with the CC genotype or may have a reduced response (lower increases in HDL-cholesterol) as compared to patients with the TT genotype. Other genetic and clin... | https://www.clinpgx.org/clinicalAnnotation/1183492235 |
1183492235 | rs2230806 | rs2230806 | ABCA1 | TT | 3 | Efficacy | pravastatin | Coronary Disease | Patients with the TT genotype and Coronary Disease who are treated with pravastatin may have a better response (increased HDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183492235 |
1183492244 | rs17655652 | rs17655652 | NPC1L1 | CC | 3 | Efficacy | pravastatin | Diabetes Mellitus;Hypertension;Vascular Diseases | Men with the CC genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to men with the CT or TT genotype. Women with the CC genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-... | https://www.clinpgx.org/clinicalAnnotation/1183492244 |
1183492244 | rs17655652 | rs17655652 | NPC1L1 | CT | 3 | Efficacy | pravastatin | Diabetes Mellitus;Hypertension;Vascular Diseases | Men with the CT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the CT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-choles... | https://www.clinpgx.org/clinicalAnnotation/1183492244 |
1183492244 | rs17655652 | rs17655652 | NPC1L1 | TT | 3 | Efficacy | pravastatin | Diabetes Mellitus;Hypertension;Vascular Diseases | Men with the TT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the TT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-choles... | https://www.clinpgx.org/clinicalAnnotation/1183492244 |
1183492249 | rs7412 | rs7412 | APOE | CC | 2B | Efficacy | atorvastatin | Coronary Disease;Hyperlipidemias | Patients with the rs7412 CC genotype may have decreased response to atorvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to atorvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183492249 |
1183492249 | rs7412 | rs7412 | APOE | CT | 2B | Efficacy | atorvastatin | Coronary Disease;Hyperlipidemias | Patients with the rs7412 CT genotype may have increased response to atorvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atorvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183492249 |
1183492249 | rs7412 | rs7412 | APOE | TT | 2B | Efficacy | atorvastatin | Coronary Disease;Hyperlipidemias | Patients with the rs7412 TT genotype may have increased response to atorvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atorvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183492249 |
1183532521 | rs12003906 | rs12003906 | ABCA1 | CC | 3 | Efficacy | atorvastatin;pravastatin;simvastatin | Hyperlipidemias | Patients with the CC genotype and Hyperlipidemia who are treated with atorvastatin, pravastatin or simvastatin may have a reduced response (less reduction in LDL-cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183532521 |
1183532521 | rs12003906 | rs12003906 | ABCA1 | CG | 3 | Efficacy | atorvastatin;pravastatin;simvastatin | Hyperlipidemias | Patients with the CG genotype and Hyperlipidemia who are treated with atorvastatin, pravastatin or simvastatin may have a reduced response (less reduction in LDL-cholesterol) as compared to patients with the GG genotype or may have a better response (a higher reduction in LDL-cholesterol) as compared to patients with t... | https://www.clinpgx.org/clinicalAnnotation/1183532521 |
1183532521 | rs12003906 | rs12003906 | ABCA1 | GG | 3 | Efficacy | atorvastatin;pravastatin;simvastatin | Hyperlipidemias | Patients with the GG genotype and Hyperlipidemia who are treated with atorvastatin, pravastatin or simvastatin may have a better response (a higher reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183532521 |
1183532576 | rs429358 | rs429358 | APOE | CC | 3 | Efficacy | simvastatin | Myocardial Infarction | Patients with the CC genotype (ApoE E4/E4) may have an increased risk of mortality after myocardial infarction as compared to the TT genotype, which may be mitigated by simvastatin treatment. Therefore, these patients may actually benefit more from simvastatin treatment. Other genetic and clinical factors may also infl... | https://www.clinpgx.org/clinicalAnnotation/1183532576 |
1183532576 | rs429358 | rs429358 | APOE | CT | 3 | Efficacy | simvastatin | Myocardial Infarction | Patients with the CT genotype (ApoE E4 carriers) may have an increased risk of mortality after myocardial infarction as compared to the TT genotype, which may be mitigated by simvastatin treatment. Therefore, these patients may actually benefit more from simvastatin treatment. Other genetic and clinical factors may als... | https://www.clinpgx.org/clinicalAnnotation/1183532576 |
1183532576 | rs429358 | rs429358 | APOE | TT | 3 | Efficacy | simvastatin | Myocardial Infarction | Patients with the TT genotype may have a decreased risk of mortality after myocardial infarction as compared to the CC or CT genotypes (ApoE E2 carriers), which may be mitigated by simvastatin treatment. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183532576 |
1183532599 | rs5888 | rs5888 | SCARB1 | AA | 3 | Efficacy | atorvastatin | Hypercholesterolemia | Patients with the AA genotype and Hypercholesterolemia who are treated with atorvastatin may have a better response to treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183532599 |
1183532599 | rs5888 | rs5888 | SCARB1 | AG | 3 | Efficacy | atorvastatin | Hypercholesterolemia | Patients with the AG genotype and Hypercholesterolemia who are treated with atorvastatin may have a reduced response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183532599 |
1183532599 | rs5888 | rs5888 | SCARB1 | GG | 3 | Efficacy | atorvastatin | Hypercholesterolemia | Patients with the GG genotype and Hypercholesterolemia who are treated with atorvastatin may have a reduced response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183532599 |
1183533592 | rs12654264 | rs12654264 | HMGCR | AA | 3 | Other | HMG-CoA reductase inhibitors | Colonic Neoplasms | Patients with the AA genotype may have a larger reduction in the risk of colon cancer when treated with statins as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for colon cancer and response to statin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183533592 |
1183533592 | rs12654264 | rs12654264 | HMGCR | AT | 3 | Other | HMG-CoA reductase inhibitors | Colonic Neoplasms | Patients with the AT genotype may have a higher reduction in the risk of colon cancer when treated with statins as compared to patients with the TT genotype or may have a lower reduction in the risk of colon cancer when treated with statins as compared to patients with the AA genotype. Other genetic and clinical factor... | https://www.clinpgx.org/clinicalAnnotation/1183533592 |
1183533592 | rs12654264 | rs12654264 | HMGCR | TT | 3 | Other | HMG-CoA reductase inhibitors | Colonic Neoplasms | Patients with the TT genotype may have a lower reduction in the risk of colon cancer when treated with statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for colon cancer and response to statin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183533592 |
1183533882 | rs328 | rs328 | LPL | CC | 3 | Efficacy | pravastatin | null | Patients with the CC genotype who are treated with pravastatin may have a reduced response (less decrease in total cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183533882 |
1183533882 | rs328 | rs328 | LPL | CG | 3 | Efficacy | pravastatin | null | Patients with the CG genotype who are treated with pravastatin may have a reduced response (less decrease in total cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183533882 |
1183533882 | rs328 | rs328 | LPL | GG | 3 | Efficacy | pravastatin | null | Patients with the GG genotype who are treated with pravastatin may have a better response (higher decreases in total cholesterol) as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183533882 |
1183533940 | rs4149015 | rs4149015 | SLCO1B1 | AA | 3 | Toxicity | irinotecan | Non-Small Cell Lung Carcinoma | Patients with the AA genotype and non-small cell lung cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia. | https://www.clinpgx.org/clinicalAnnotation/1183533940 |
1183533940 | rs4149015 | rs4149015 | SLCO1B1 | AG | 3 | Toxicity | irinotecan | Non-Small Cell Lung Carcinoma | Patients with the AG genotype and non-small cell lung cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia. | https://www.clinpgx.org/clinicalAnnotation/1183533940 |
1183533940 | rs4149015 | rs4149015 | SLCO1B1 | GG | 3 | Toxicity | irinotecan | Non-Small Cell Lung Carcinoma | Patients with the GG genotype and non-small cell lung cancer may have a decreased risk of neutropenia when treated with irinotecan as compared to patients with the AG or GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia. | https://www.clinpgx.org/clinicalAnnotation/1183533940 |
1183533945 | rs3740066 | rs3740066 | ABCC2 | CC | 3 | Toxicity | irinotecan | Non-Small Cell Lung Carcinoma | Patients with the CC genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the CT or TT genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea. | https://www.clinpgx.org/clinicalAnnotation/1183533945 |
1183533945 | rs3740066 | rs3740066 | ABCC2 | CT | 3 | Toxicity | irinotecan | Non-Small Cell Lung Carcinoma | Patients with the CT genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea. | https://www.clinpgx.org/clinicalAnnotation/1183533945 |
1183533945 | rs3740066 | rs3740066 | ABCC2 | TT | 3 | Toxicity | irinotecan | Non-Small Cell Lung Carcinoma | Patients with the TT genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea. | https://www.clinpgx.org/clinicalAnnotation/1183533945 |
1183533950 | rs3025000 | rs3025000 | VEGFA | CC | 3 | Efficacy | bevacizumab;ranibizumab | Macular Degeneration | Patients with the CC genotype and macular degeneration may have a poorer response when treated with bevacizumab or ranibizumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab. | https://www.clinpgx.org/clinicalAnnotation/1183533950 |
1183533950 | rs3025000 | rs3025000 | VEGFA | CT | 3 | Efficacy | bevacizumab;ranibizumab | Macular Degeneration | Patients with the CT genotype and macular degeneration may have a better response when treated with bevacizumab or ranibizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab. | https://www.clinpgx.org/clinicalAnnotation/1183533950 |
1183533950 | rs3025000 | rs3025000 | VEGFA | TT | 3 | Efficacy | bevacizumab;ranibizumab | Macular Degeneration | Patients with the TT genotype and macular degeneration may have a better response when treated with bevacizumab or ranibizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab. | https://www.clinpgx.org/clinicalAnnotation/1183533950 |
1183533955 | rs3024530 | rs3024530 | IL4R | AA | 3 | Efficacy | pitrakinra | Asthma | Patients with the AA genotype and asthma may have a reduced frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to pitrakinra. | https://www.clinpgx.org/clinicalAnnotation/1183533955 |
1183533955 | rs3024530 | rs3024530 | IL4R | AG | 3 | Efficacy | pitrakinra | Asthma | Patients with the AG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra. | https://www.clinpgx.org/clinicalAnnotation/1183533955 |
1183533955 | rs3024530 | rs3024530 | IL4R | GG | 3 | Efficacy | pitrakinra | Asthma | Patients with the GG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra. | https://www.clinpgx.org/clinicalAnnotation/1183533955 |
1183533961 | rs2740574 | rs2740574 | CYP3A4 | CC | 4 | Efficacy | amlodipine | Hypertension | Women with the CC genotype and hypertension may have a decreased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg when treated with amlodipine as compared to women with the CT or TT genotype. No significant associations were seen when considering a target mean arterial pressure of <= 92 mm Hg, or ... | https://www.clinpgx.org/clinicalAnnotation/1183533961 |
1183533961 | rs2740574 | rs2740574 | CYP3A4 | CT | 4 | Efficacy | amlodipine | Hypertension | Women with the CT genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg when treated with amlodipine as compared to women with the CC genotype. No significant associations were seen when considering a target mean arterial pressure of <= 92 mm Hg, or when ... | https://www.clinpgx.org/clinicalAnnotation/1183533961 |
1183533961 | rs2740574 | rs2740574 | CYP3A4 | TT | 4 | Efficacy | amlodipine | Hypertension | Women with the TT genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg when treated with amlodipine as compared to women with the CC genotype. No significant associations were seen when considering a target mean arterial pressure of <= 92 mm Hg, or when ... | https://www.clinpgx.org/clinicalAnnotation/1183533961 |
1183533966 | rs2305089 | rs2305089 | TBXT | CC | 3 | Efficacy | flunisolide | Asthma | Patients with the CC genotype and asthma may have a poorer response when treated with flunisolide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to flunisolide. | https://www.clinpgx.org/clinicalAnnotation/1183533966 |
1183533966 | rs2305089 | rs2305089 | TBXT | CT | 3 | Efficacy | flunisolide | Asthma | Patients with the CT genotype and asthma may have a poorer response when treated with flunisolide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to flunisolide. | https://www.clinpgx.org/clinicalAnnotation/1183533966 |
1183533966 | rs2305089 | rs2305089 | TBXT | TT | 3 | Efficacy | flunisolide | Asthma | Patients with the TT genotype and asthma may have a better response when treated with flunisolide as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to flunisolide. | https://www.clinpgx.org/clinicalAnnotation/1183533966 |
1183533972 | rs2301339 | rs2301339 | GNB3 | AA | 3 | Efficacy | atenolol | Essential hypertension | Women with the AA genotype and hypertension may have smaller decreases in systolic or diastolic blood pressure when treated with atenolol as compared to women with the GG genotype. No significant results were seen in men. When considering systolic blood pressure only, significant results were seen for men and women com... | https://www.clinpgx.org/clinicalAnnotation/1183533972 |
1183533972 | rs2301339 | rs2301339 | GNB3 | AG | 3 | Efficacy | atenolol | Essential hypertension | Women with the AG genotype and hypertension may have smaller decreases in systolic blood pressure when treated with atenolol as compared to women with the GG genotype. The same result was seen for women and men combined; no significant results were seen in men. Other genetic and clinical factors may also influence syst... | https://www.clinpgx.org/clinicalAnnotation/1183533972 |
1183533972 | rs2301339 | rs2301339 | GNB3 | GG | 3 | Efficacy | atenolol | Essential hypertension | Women with the GG genotype and hypertension may have greater decreases in systolic or diastolic blood pressure when treated with atenolol as compared to women with the AA or AG genotype. No significant results were seen in men. When considering systolic blood pressure only, significant results were seen for men and wom... | https://www.clinpgx.org/clinicalAnnotation/1183533972 |
1183533981 | rs2290732 | rs2290732 | GABRA1 | AA | 3 | Efficacy | carbamazepine | Epilepsy | Patients with the AA genotype and epilepsy may have increased retention rates when treated with carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence retention rate of carbamazepine. | https://www.clinpgx.org/clinicalAnnotation/1183533981 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.